These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 30686636)

  • 1. Effect of atorvastatin on humoral immune response to 23-valent pneumococcal polysaccharide vaccination in healthy volunteers: The StatVax randomized clinical trial.
    Wildes TJ; Grippin A; Fasanya H; Dyson KA; Brantly M
    Vaccine; 2019 Feb; 37(10):1313-1324. PubMed ID: 30686636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant system AS02V enhances humoral and cellular immune responses to pneumococcal protein PhtD vaccine in healthy young and older adults: randomised, controlled trials.
    Leroux-Roels I; Devaster JM; Leroux-Roels G; Verlant V; Henckaerts I; Moris P; Hermand P; Van Belle P; Poolman JT; Vandepapelière P; Horsmans Y
    Vaccine; 2015 Jan; 33(4):577-84. PubMed ID: 24176494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers.
    Udani JK; Singh BB; Barrett ML; Singh VJ
    Nutr J; 2010 Aug; 9():32. PubMed ID: 20796315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1 Randomized, Placebo-controlled, Observer-blinded Trial to Evaluate the Safety and Immunogenicity of Inactivated Streptococcus pneumoniae Whole-cell Vaccine in Adults.
    Keech CA; Morrison R; Anderson P; Tate A; Flores J; Goldblatt D; Briles D; Hural J; Malley R; Alderson MR
    Pediatr Infect Dis J; 2020 Apr; 39(4):345-351. PubMed ID: 31895881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, reactogenicity and immunogenicity of a novel pneumococcal protein-based vaccine in adults: a phase I/II randomized clinical study.
    Leroux-Roels G; Maes C; De Boever F; Traskine M; Rüggeberg JU; Borys D
    Vaccine; 2014 Nov; 32(50):6838-46. PubMed ID: 24607003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity and safety of a 23-valent pneumococcal polysaccharide vaccine in Chinese healthy population aged >2 years: A randomized, double-blinded, active control, phase III trial.
    Kong Y; Zhang W; Jiang Z; Wang L; Li C; Li Y; Xia J
    Hum Vaccin Immunother; 2015; 11(10):2425-33. PubMed ID: 26083953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Jackson LA; Gurtman A; Rice K; Pauksens K; Greenberg RN; Jones TR; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3585-93. PubMed ID: 23688527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients.
    Migita K; Akeda Y; Akazawa M; Tohma S; Hirano F; Ideguchi H; Kozuru H; Jiuchi Y; Matsumura R; Suematsu E; Miyamura T; Mori S; Fukui T; Izumi Y; Iwanaga N; Tsutani H; Saisyo K; Yamanaka T; Ohshima S; Mori N; Matsumori A; Takahi K; Yoshizawa S; Kawabe Y; Suenaga Y; Ozawa T; Hamada N; Komiya Y; Matsui T; Furukawa H; Oishi K
    Arthritis Res Ther; 2015 Dec; 17():357. PubMed ID: 26653668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of the 13-valent Pneumococcal Conjugate vaccine in 23-valent pneumococcal polysaccharide vaccine-naive and pre-immunized patients under treatment with chronic haemodialysis: a longitudinal quasi-experimental phase IV study.
    Vandecasteele SJ; De Bacquer D; Caluwe R; Ombelet S; Van Vlem B
    Clin Microbiol Infect; 2018 Jan; 24(1):65-71. PubMed ID: 28559003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in adults 50 to 65 years of age in India: An open-label trial.
    Solanki BB; Juergens C; Chopada MB; Supe P; Sundaraiyer V; Le Dren-Narayanin N; Cutler MW; Gruber WC; Scott DA; Schmoele-Thoma B
    Hum Vaccin Immunother; 2017 Sep; 13(9):2065-2071. PubMed ID: 28881165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine responses in patients with rheumatoid arthritis treated with certolizumab pegol: results from a single-blind randomized phase IV trial.
    Kivitz AJ; Schechtman J; Texter M; Fichtner A; de Longueville M; Chartash EK
    J Rheumatol; 2014 Apr; 41(4):648-57. PubMed ID: 24584918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Zinc Supplementation on Serological Response to Vaccination Against Streptococcus Pneumoniae in Patients Undergoing Chemotherapy for Colorectal Cancer.
    Braga CB; Santos IK; Palmeira P; Peria FM; Ribeiro SM; Martinez EZ; da Rocha JJ; da Cunha SF
    Nutr Cancer; 2015; 67(6):926-32. PubMed ID: 26134076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repeat pneumococcal polysaccharide vaccine in Indigenous Australian adults is associated with decreased immune responsiveness.
    Moberley S; Licciardi PV; Balloch A; Andrews R; Leach AJ; Kirkwood M; Binks P; Mulholland K; Carapetis J; Tang MLK; Skull S
    Vaccine; 2017 May; 35(22):2908-2915. PubMed ID: 28455171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of 23-Valent Pneumococcal Vaccine in Children with Systemic Lupus Erythematosus.
    Alyasin S; Adab M; Hosseinpour A; Amin R; Babaei M
    Iran J Immunol; 2016 Sep; 13(3):204-19. PubMed ID: 27671512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between asthma status and antibody response pattern to 23-valent pneumococcal vaccination.
    Sheen YH; Kizilbash S; Ryoo E; Wi CI; Park M; Abraham RS; Ryu E; Divekar R; Juhn Y
    J Asthma; 2020 Apr; 57(4):381-390. PubMed ID: 30784333
    [No Abstract]   [Full Text] [Related]  

  • 17. Methotrexate reduces vaccine-specific immunoglobulin levels but not numbers of circulating antibody-producing B cells in rheumatoid arthritis after vaccination with a conjugate pneumococcal vaccine.
    Kapetanovic MC; Nagel J; Nordström I; Saxne T; Geborek P; Rudin A
    Vaccine; 2017 Feb; 35(6):903-908. PubMed ID: 28081972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
    Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
    Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
    Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
    Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults.
    Schmoele-Thoma B; van Cleeff M; Greenberg RN; Gurtman A; Jones TR; Sundaraiyer V; Gruber WC; Scott DA
    Hum Vaccin Immunother; 2019; 15(3):575-583. PubMed ID: 30648932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.